IN BRIEF: Arix Bioscience investee Artios collaborates with Novartis

Arix Bioscience PLC - firm which invests in biotech companies - Notes that its portfolio company ...

Alliance News 7 April, 2021 | 8:00PM
Email Form Facebook Twitter LinkedIn RSS

Arix Bioscience PLC - firm which invests in biotech companies - Notes that its portfolio company Artios Pharma Ltd announced a global research collaboration with Novartis AG to discover and validate next generation DNA damage response targets to enhance Novartis' radioligand therapies. Novartis will make an up-front payment of USD20 million and provide near term research funding to support the collaboration. Artios will be eligible to receive discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of products commercialised by Novartis.

Arix is the largest shareholder in Artios, with a 12% stake.

Current stock price: 190.00 pence, up 1.1% on Wednesday

Year-to-date change: down 13%

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Arix Bioscience PLC 158.00 GBX -1.25 -
Novartis AG 76.66 CHF -0.39

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement